CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Strata Critical Medical Q3 revenue beats estimates; announces buyback

By Reuters News


Overview

  • US medical logistics and clinical services firm's Q3 revenue rose 50% yr/yr, beating analyst expectations

  • Adjusted EBITDA more than doubled yr/yr, driven by clinical segment acquisitions

  • Company authorized $20 mln share repurchase program


Outlook

  • Strata reiterates 2026 revenue guidance of $285-295 mln

  • Company maintains 2026 adjusted EBITDA outlook at $33-35 mln

  • Strata expects 2026 free cash flow, before aircraft and engine acquisitions, of $15-22 mln


Result Drivers

  • CLINICAL ACQUISITIONS - Co said revenue growth was driven by a full quarter contribution from Keystone acquisition and three acquisitions completed in Q2

  • LOGISTICS SEGMENT - Logistics revenue declined yr/yr, attributed to increased fuel surcharge pass through revenue and shorter average donor-recipient distances, resulting in lower margins on owned aircraft

  • CLINICAL MARGIN EXPANSION - Clinical gross margin increased yr/yr, supported by acquisitions and modest organic growth, though sequential margin declined due to staff and training investments


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$74.08 mln

$72.67 mln (4 Analysts)

Q3 Operating Expenses

$20.65 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the courier, postal, air freight & land-based logistics peer group is "buy"

  • Wall Street's median 12-month price target for Strata Critical Medical, Inc. is $8.75, about 104.4% above its November 2 closing price of $4.28

  • The stock recently traded at 82 times the next 12-month earnings vs. a P/E of 147 three months ago


Reuters Recommended Reads

  • Nov 2 - IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook

  • Nov 3 - Amneal Q3 revenue beats estimates on affordable medicines growth; outlook raised

  • Nov 2 - Tempus AI Q3 revenue slightly beats estimates; raises guidance


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.